… inhibitors inactivates FVIII by proteolysis. We discuss therapeutic approaches currently used
for treatment of hemophilia A patients with inhibitors … the level of inhibitors and consideration …

… review focuses on the development of inhibitors in patients with congenital hemophilia,
which is the most serious treatment-related complication in these patients. Hemophilia A (HA) is …

… The specific antibody responses to A2, A3, and C2 vary considerably among individuals,
and epitopes for inhibitor antibodies have been determined for all three. The anti-C2 inhibitors …

… there are at least three different types of inhibitor antibodies in the NS plasma, but because
… is the sole inhibitor measured in the neutralization assay. The anti-LCh antibodies appear to …

… antibody emicizumab (Hemlibra) that mimics the cofactor activity of activated factor VIII (FVIII)
has been approved for treatment of hemophilia A patients with and without inhibitor. In the …

… patients with hemophilia A or B or acquired hemophilia are treated with a method developed
for temporary removal of inhibitory antibodies, … adsorption of the antibodies to protein A-…

… patients without FVIII inhibitors and in healthy subjects. In addition, FVIII-specific antibodies
in hemophilia A patients with inhibitors … of antibodies found in patients without inhibitors or in …

… Inhibitor antibodies to factor VIII arise in a substantial minority of patients with hemophilia
A treated with replacement therapy; factor IX inhibitors in treated hemophilia B patients are …

… In order to overcome the inhibitory antibodies, bleeding episodes in LTI patients with hemophilia
… An alternate therapy for hemophilia A patients with inhibitors, is the use of porcine FVIII …

… monoclonal antibody exhibiting the same property. We conclude that the present inhibitors
… The inhibition of wild-type FVIII by LE antibody is enhanced by vWF and is associated with …